U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07427628) titled 'A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis' on Jan. 23.
Brief Summary: The purpose of this Phase 1, first in uveitis open-label study is to assess the safety and tolerability of TRX-103 in patients with non infectious uveitis (NIU). It is anticipated that up to 18 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Non Infectious Uveitis
Intervention:
BIOLOGICAL: TRX103
TRX103 infusion via peripheral line
Recruitment Status...